637 research outputs found
Estudio comparativo de las propiedades magnéticas de ferritas hexagonales de Bario obtenidas por los métodos de coprecipitación y microemulsión
Por el m todo de coprecipitaci n qu mica se obtuvo un precursor formado por hidr xidos y carbonatos de hierro y bario que
al calcinarlo a temperaturas superiores a 730oC se transforma en ferrita de bario. Al calcinar el precursor durante 2 horas se
obtuvo la magnetizaci n m xima de 59.1 emu/g para la temperatura de 925oC. Por el m todo de microemulsi n se obtuvo
un precursor fino de hidr xidos y carbonatos de hierro y bario que al calcinarlo a temperaturas superiores a 760oC se transforma
en ferrita de bario. Al calcinar el precursor durante 12 horas se obtuvo la magnetizaci n m xima de 60.5 emu/g para
la temperatura de 925oC. La coercitividad intr nseca del polvo de ferrita de bario obtenido por microemulsi n result ser un
20% menor que la coercitividad intr nseca del polvo de ferrita de bario obtenido por coprecipitaci n. Esta menor coercitividad
debe favorecer al m todo de microemulsi n para la producci n de part culas de ferrita de bario que sirvan como medio de
grabaci n magn tica perpendicular.Peer reviewe
CD8 (+)/V beta 5.1(+) large granular lymphocyte leukemia associated with autoimmune cytopenias, rheumatoid arthritis and vascular mammary skin lesions: successful response to 2‐deoxycoformycin.
Hematol Oncol. 2002 Jun;20(2):87-93.
Cd8(+)/V beta 5.1(+) large granular lymphocyte leukemia associated with autoimmune cytopenias, rheumatoid arthritis and vascular mammary skin lesions: successful response to 2-deoxycoformycin.
Granjo E, Lima M, Correia T, Lisboa C, Magalhães C, Cunha N, Teixeira MA, Queirós ML, Candeias J, Matutes E.
Department of Clinical Haematology, Hospital Geral de São João, Porto, Portugal. [email protected]
Abstract
We report a case of CD8(+)/V beta 5.1(+) T-cell large granular lymphocyte leukemia (T-LGL leukemia) presenting with mild lymphocytosis, severe autoimmune neutropenia, thrombocytopenia, polyarthritis and recurrent infections with a chronic disease course. Immunophenotyping showed an expansion of CD3(+)/TCR alpha beta(+)/CD8(+bright)/CD11c(+)/CD57(-)/CD56(-) large granular lymphocytes with expression of the TCR-V beta 5.1 family. Southern blot analysis revealed a clonal rearrangement of the TCR beta-chain gene. Hematopoietic growth factors, high dose intravenous immunoglobulin and corticosteroids were of limited therapeutic benefit to correct the cytopenias. During the disease course, the patient developed a severe cutaneous leg ulcer and bilateral vascular mammary skin lesions. Treatment with 2-deoxycoformycin resulted in both clinical and hematological complete responses, including the resolution of vascular skin lesions. Combined immuno-staining with relevant T-cell associated and anti-TCR-V beta monoclonal antibodies proved to be a sensitive method to assess the therapeutic effect of 2-deoxycoformicin and to evaluate the residual disease.
Copyright 2002 John Wiley & Sons, Ltd.
PMID: 12111871 [PubMed - indexed for MEDLIN
Intraclonal diversity in a Sezary syndrome with a differential response to 2‐deoxycoformycin of the two lymphoma cell populations
Br J Haematol. 2002 Dec;119(3):629-33.
Intraclonal diversity in a Sezary syndrome with a differential response to 2-deoxycoformycin of the two lymphoma cell populations.
Granjo E, Lima M, Lopes JM, Cunha N, Teixeira Mdos A, Santos F, Candeias J, Resende C, Santos AH, Balanzategui A, Orfão A, Matutes E.
Department of Clinical Haematology, Hospital Geral de São João, Porto, Portugal. [email protected]
Abstract
We report a case of Sezary syndrome with two abnormal CD4+ T-cell populations detected in the peripheral blood by flow cytometry immunophenotyping and DNA cell content, suggesting a biclonal T-cell lymphoproliferative disorder. Despite these findings, molecular analysis of the T-cell receptor genes was consistent with a monoclonal T-cell proliferation, supporting the existence of intraclonal diversity rather than a true biclonal disease. The patient achieved a transient response with 2-deoxycoformycin, with a selective decrease of the larger/hyperploid T-cell population; later on, an increased representation of this T-cell population was observed concomitantly with clinical relapse.
PMID: 12437636 [PubMed - indexed for MEDLINE
Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping
Immunophenotypic characterization of B-cell chronic lymphoproliferative disorders (B-CLPD) is becoming increasingly complex due to usage of progressively larger panels of reagents and a high number of World Health Organization (WHO) entities. Typically, data analysis is performed separately for each stained aliquot of a sample; subsequently, an expert interprets the overall immunophenotypic profile (IP) of neoplastic B-cells and assigns it to specific diagnostic categories. We constructed a principal component analysis (PCA)-based tool to guide immunophenotypic classification of B-CLPD. Three reference groups of immunophenotypic data files—B-cell chronic lymphocytic leukemias (B-CLL; n=10), mantle cell (MCL; n=10) and follicular lymphomas (FL; n=10)—were built. Subsequently, each of the 175 cases studied was evaluated and assigned to either one of the three reference groups or to none of them (other B-CLPD). Most cases (89%) were correctly assigned to their corresponding WHO diagnostic group with overall positive and negative predictive values of 89 and 96%, respectively. The efficiency of the PCA-based approach was particularly high among typical B-CLL, MCL and FL vs other B-CLPD cases. In summary, PCA-guided immunophenotypic classification of B-CLPD is a promising tool for standardized interpretation of tumor IP, their classification into well-defined entities and comprehensive evaluation of antibody panels
T-cell prolymphocytic leukaemia: spontaneous immunophenotypical switch from CD4 to CD8 expression
published_or_final_versionSpringer Open Choice, 21 Feb 201
- …